How to improve accrual to clinical trials of symptom control 2: design issues

Area of Science:

• Integrative oncology
• Clinical trial design
• Patient accrual

Background:

• Clinical trials in integrative oncology frequently fail due to insufficient patient numbers.
• Overly restrictive eligibility criteria are a primary cause of poor patient accrual.
• Excessive patient participation burdens can also negatively impact recruitment.

Purpose of the Study:

• To identify key factors hindering patient accrual in integrative oncology clinical trials.
• To propose strategies for optimizing clinical trial design to improve patient recruitment.
• To ensure the benefits of participation outweigh the burdens for patients in clinical studies.

Main Methods:

• Critical examination of inclusion and exclusion criteria in clinical trial protocols.
• Assessment of patient participation burdens, including travel and data collection.
• Evaluation of strategies to enhance patient-reported benefits, such as guaranteed treatment for control groups.

Main Results:

• Restrictive eligibility criteria significantly reduce the potential patient pool.
• High patient burden, including travel and excessive questionnaires, deters participation.
• Failure to ensure perceived benefits can lead to patient withdrawal or non-participation.

Conclusions:

• Investigators must rigorously assess each criterion for its impact on accrual versus study benefit.
• Minimizing patient burden through fewer visits and streamlined data collection is crucial.
• Strategies guaranteeing treatment benefits, even for control groups, can enhance participation in oncology trials.